PLT Health Solutions Unveils Second Clinical Study on Beverage-Friendly Dynagenix® Muscle+Joint Formula Demonstrating Enhanced Mobility & Rapid Joint Comfort within Five Days

Clinically validated Boswellia serrata ingredient now backed by two human studies supporting joint comfort, flexibility, muscle recovery, and functional mobility

MORRISTOWN, N.J., Oct. 14, 2025 /PRNewswire/ -- PLT Health Solutions, Inc., in collaboration with Laila Nutraceuticals, today announced the completion of a second clinical study on its next generation Dynagenix^® Muscle+Joint Formula. Dynagenix is an innovative, low-dose Boswellia serrata extract in a neutral-tasting, water-soluble form, making it ideal for formulating into contemporary delivery systems. The newest study demonstrated that just 40 mg/day of Dynagenix led to statistically significant improvements in joint comfort, stiffness, and function as early as 5 days after initial supplementation.

Within 15 days, participants experienced enhanced flexibility and improved physical performance with the 30-day results showing compelling gains across a broad range of mobility metrics. Previous studies on Dynagenix have demonstrated its effectiveness, not only for the joint discomfort, but also for next-day muscle and joint recovery after exercise, with significantly reduced muscle soreness and recovery of strength for a total musculoskeletal solution.

"This second clinical study validates Dynagenix as a true category-advancing ingredient," said Seth Flowerman, CEO of PLT Health Solutions. "It offers fast, meaningful results in joint and muscle comfort—whether you're an athlete returning to activity or someone looking to move through daily life with less discomfort and more ease. And thanks to its low-dose, water-soluble form, it offers exciting innovation potential for formulators," he added.

Clinical Results: Enhanced Function in Just 5 Days
The randomized, double-blind, placebo-controlled study evaluated 72 men and women (age 40-70) with Grade II osteoarthritis. Subjects received either 40 mg/day of Dynagenix or a matching placebo for 30 days. Key outcome measures tested were WOMAC pain, stiffness, and function; a 30-second Chair Stand Test; a 6-minute Walk Test; a Stair Climb Test; and knee flexion and range of motion. Biomarkers of inflammation were also evaluated. Subjects were assessed at baseline, 5, 15, and 30 days.
In addition to the fast-acting effects seen at 5 and 15 days, by 30 days, based on the WOMAC scale, subjects consuming Dynagenix experienced:

• 47% improvement in joint comfort
• 47% reduction in joint stiffness
• 45% improvement in joint function
• 46% improvement in overall joint health

Functional performance results included:

• 25% increase in Chair Stand Test performance at 2 weeks
• 25% faster stair navigation (4 seconds faster)
• 15.4% increase in walking speed, with subjects walking 47 meters farther in 6 minutes
• 14% improvement in flexibility

Expanded Clinical Platform: From Recovery to Resilience
This new study builds on a 2019 clinical trial using a Delayed Onset Muscle Soreness (DOMS) model in recreationally active men. That study showed that 60 mg/day of Dynagenix significantly:

• Reduced muscle soreness by up to 47%
• Reduced joint soreness during exercise by 31%
• Increased strength recovery, with 96% of subjects regaining full strength by Day 3—2.5x higher than placebo
• Lowered perceived exertion by up to 27%
• Improved inflammatory biomarkers related to muscle and connective tissue stress

"Dynagenix now has robust data across two different populations and usage occasions," said Jennifer Murphy, Director of Innovation & Clinical Development at PLT. "From reducing soreness and accelerating recovery post-exercise to improving everyday joint function in older adults, Dynagenix delivers fast, measurable benefits at a very low 40mg effective dose." she said. "At PLT we are enthusiastic about how these results will allow brands to deliver superior joint health support across a wider range of palatable, easy-to-consumer products n consumer-preferred formats like gummies, shots, sachets, and stick-packs, and expand its potential for helping people live happier, healthier lives," she added.

Innovation-Ready for Modern Delivery Systems

Dynagenix's neutral taste and water solubility make it ideal for a wide range of taste-sensitive, consumer-friendly delivery formats, including:

• Ready-to-mix powders
• Functional chews and gummies
• Stick-packs
• Shots and shakes

This formulation flexibility enables product developers to create clinically substantiated offerings across key categories like sports nutrition, joint health, active aging, and everyday recovery.

For more information on the study or Dynagenix Muscle+Joint Formula, visit www.plthealth.com/dynagenix.

Media Contact:
Mark Falconer
Sciencewerks
407-412-9705
E-mail: [email protected]

Company Contact:
Steve Fink
PLT Health Solutions, Inc.
973-984-0900 x214
E-mail: [email protected]

SOURCE PLT Health Solutions